Tesamorelin

What it's for

Tesamorelin is a stabilized GHRH (growth-hormone–releasing hormone, a brain signal that asks the pituitary to release growth hormone) analog that stimulates pituitary growth hormone secretion. It reduces excess abdominal visceral adipose tissue in adults with HIV-associated lipodystrophy.

What it does for the body

It reduces excess abdominal visceral adipose tissue in adults with HIV-associated lipodystrophy. It is not approved as a general fat-loss or bodybuilding drug. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

GHRH (growth-hormone–releasing hormone, a brain signal that asks the pituitary to release growth hormone) receptors (lock-and-key landing spots on cells) activation increases endogenous growth hormone pulses, raising IGF-1 and shifting lipid metabolism in a way that can reduce visceral fat in the labeled population. Imagine a thermostat for growth-hormone release: some peptides nudge the brain's release signals up, rather than pouring hormone in directly.

Research context

Bottom line for readers: Tesamorelin has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Digestive research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Tesamorelin — FDA.gov search
• ClinicalTrials.gov search: Tesamorelin — U.S. clinical trials registry
• Drugs@FDA search: Tesamorelin — FDA drug database (if approved)
• PubMed search: Tesamorelin — NCBI PubMed
• PubMed Central search: Tesamorelin — NCBI PMC

Reference

No ref on file.